Clinical Weight Loss Protocol
B84· Mostly solidInvestigational/clinical agents with strong RCT evidence in obesity-related indications (not supplements).
Track how this stack felt, what you want to change next cycle, or anything you want to save privately in your member zone.
Pre-check is rule-based, not medical advice. Consult a healthcare professional for personalised guidance.
Interaction analysis is based on peer-reviewed pharmacology. PMID links go to PubMed. Not medical advice.
Morning • Other • Human phase 2 RCT evidence for weight loss in obesity.1mg
Retatrutide produced substantial mean body-weight reductions over 48 weeks (up to ~24% at highest dose), with larger losses at higher doses; GI adverse effects were common & dose-related.
The TRIUMPH phase 3 program (4 trials, >5800 participants) evaluates once-weekly subcutaneous retatrutide vs. placebo for weight management & obesity-related complications (OSA, OA, CVD). No primary efficacy results published as of early 2026; design & rationale published in 2025.
CagrilintideHighPLACEHOLDER • Other • Clinical trial evidence in obesity programs (often combination development).1mg
CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg once weekly) produced an estimated mean body-weight reduction of -20.4% vs -3.0% with placebo at week 68 (P<0.001), superior to either component alone. GI adverse events were common (majority transient & mild-to-moderate). Published in NEJM 2025.
CagriSema produced mean weight loss of -13.7% vs -3.4% with placebo at week 68, & 73.5% of patients achieved HbA1c ≤6.5% vs 15.9% with placebo. GI adverse events in 72.5% of CagriSema group (mostly transient/mild-moderate). Published in NEJM 2025.
Reuters news report (February 2026) described CagriSema outperforming semaglutide in a late-stage diabetes trial; this is now confirmed by the peer-reviewed REDEFINE 2 NEJM paper (see above).
400mg
Loose stools at higher doses; glycinate form is better tolerated than citrate or oxide
Context: doses >400mg elemental
Drowsiness — take in the evening to leverage rather than fight this effect
250 mg elemental magnesium as bisglycinate modestly but significantly reduced Insomnia Severity Index score vs. placebo (−3.9 vs −2.3, p=0.049) by week 4; well-tolerated with minimal GI effects.
Magnesium supplementation reduced sleep onset latency by ~17 min vs. placebo; increased sleep time & efficiency. Evidence rated low-to-very-low quality; all trials at moderate-to-high bias risk.
Similar community stacks
Avoid reinventing the wheel: fork a community stack that matches your category tags, then edit it.
Groups gut-inflammation oriented peptides (mostly studied in preclinical colitis/inflammation models).
Adds a copper peptide often discussed in cosmetic/skin contexts to a recovery/joint pairing. Evidence is indirect & component-based.
Non-stimulant cognitive/calm pairing commonly discussed in nootropic communities.